1. A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia–reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery. (10th March 2015) Authors: Opfermann, P; Derhaschnig, U; Felli, A; Wenisch, J; Santer, D; Zuckermann, A; Dworschak, M; Jilma, B; Steinlechner, B Journal: Clinical and experimental immunology Issue: Volume 180:Number 1(2015:Apr.) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗